[Baiyunshan: subsidiary receives therapeutic dual-plasmid HBV DNA vaccine phase IIc clinical research report] June 1, Baiyunshan announcement, recently, the company's holding subsidiary Yigan Bio launched therapeutic dual-plasmid HBV DNA vaccine phase IIc clinical trial scheme An and plan B obtained the therapeutic dual-plasmid HBV DNA vaccine phase IIc clinical research report. Therapeutic double-plasmid HBV DNA vaccine is a kind of therapeutic nucleic acid vaccine, which can induce HBV-specific cellular immunity and humoral immunity, thus play a role in the treatment of hepatitis B.